Bayesian Statistics Approach Offers Benefits To Sponsors, FDA Staffers Say
This article was originally published in The Gray Sheet
Use of Bayesian statistics in designing Guidant's Multi-Link Duet stent trial would have halved the number of enrollees required for FDA approval, according to Guidant Senior Biostatistician Frank Hu.
You may also be interested in...
FDA is encouraging medical device firms to consider using Bayesian estimation in clinical trials to streamline regulatory timeframes
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.